In recent trading session, Ginkgo Bioworks Holdings Inc (NYSE:DNA) saw 0.42 million shares changing hands at last check today with its beta currently measuring 1.16. Company’s recent per share price level of $11.71 trading at $0.28 or 2.45% at last check today assigns it a market valuation of $673.07M. That most recent trading price of DNA’s stock is at a discount of -449.96% from its 52-week high price of $64.40 and is indicating a premium of 55.08% from its 52-week low price of $5.26.

For Ginkgo Bioworks Holdings Inc (DNA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 3.83. Splitting up the data highlights that, out of 5 analysts covering the stock, 2 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -1.3 in the current quarter.

Ginkgo Bioworks Holdings Inc (NYSE:DNA) trade information

Upright in the green today for gaining 2.45%, in the last five days DNA remained trading in the red while hitting it’s week-highest on Tuesday, 02/18/25 when the stock touched $11.71 price level, adding 26.63% to its value on the day. Ginkgo Bioworks Holdings Inc’s shares saw a change of 19.25% in year-to-date performance and have moved -13.58% in past 5-day. Ginkgo Bioworks Holdings Inc (NYSE:DNA) showed a performance of -9.22% in past 30-days.

Wall Street analysts have assigned a consensus price target of 7 to the stock, which implies a fall of -67.29% to its recent value today. Analysts have been projecting 7 as a low price target for the stock while placing it at a high target of 7. It follows that stock’s current price would jump 40.22% in reaching the projected high whereas dropping to the targeted low would mean a gain of 40.22% for stock’s current value.

Ginkgo Bioworks Holdings Inc (DNA) estimates and forecasts

This year revenue growth is estimated to fall -9.45% from the last financial year’s standing.

5 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 44.43M for the same. And 4 analysts are in estimates of company making revenue of 44.24M in the next quarter. Company posted 34.76M and 37.94M of sales in current and next quarters respectively a year earlier.

In 2025, company’s earnings growth rate is likely to be around 45.22% while estimates for its earnings growth in next 5 years are of 43.25%.

Ginkgo Bioworks Holdings Inc (NYSE:DNA)’s Major holders

VIKING GLOBAL INVESTORS LP is the top institutional holder at DNA for having 143.09 million shares of worth $47.83 million. And as of 2024-06-30, it was holding 7.1383 of the company’s outstanding shares.

The second largest institutional holder is VANGUARD GROUP INC, which was holding about 138.96 million shares on 2024-06-30. The number of shares represents firm’s hold over 6.9327 of outstanding shares, having a total worth of $46.46 million.

On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024, the former fund manager was holding 1.17 shares of worth $13.71 million or 2.59% of the total outstanding shares. The later fund manager was in possession of 526.35 shares on Sep 30, 2024, making its stake of worth around $6.18 million in the company or a holder of 1.16% of company’s stock.